在CMV高风险脏移植后,对患有白血病的患者进行CMV管理
Amina Abu-Omar1, Janine Mihm2, Saskia Bronder3
1Department of Transplant and Infection Immunology, Saarland University, Homburg, Germany; Department of Internal Medicine IV, Saarland University, Homburg, Germany.
Transplant immunology
|February 1, 2025
概括
瓦尔甘西克洛维尔 (VGCV) 预防细胞巨乳病毒 (CMV) 可能导致白血病. 然而,白血患者没有面临更高的CMV感染风险,CMV静脉注射免疫球蛋白 (IVIg) 有助于更快的恢复和减少病毒载量.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 移植免疫学 移植免疫学
- 传染性疾病 传染性疾病
背景情况:
- 用瓦尔根西克洛维尔 (VGCV) 进行细胞巨乳病毒 (CMV) 预防是高风险移植患者的标准.
- 管理与VGCV相关的白血病以预防CMV初级感染是一个临床挑战.
研究的目的:
- 调查VGCV预防期间白血病对脏移植接受者的CMV风险的影响.
- 评估CMV-静脉注射免疫球蛋白 (CMV-IVIg) 在管理VGCV诱导的白血病和CMV结局方面的疗效.
主要方法:
- 对57名CMV血清阳性捐赠者的血清阴性接受者的回顾性分析 (2008-2021年).
- 在VGCV预防期间评估白血病的发展.
- 分析了与白血病和CMV-IVg管理有关的CMV风险和CMV特异性T细胞反应.
主要成果:
- 在19/57名患者中发生白血病,在VGCV治疗10周后显著增加 (p=0.0003).
- 白细胞的复制速度更快,在VGCV停止后增加了CMV-IVIg (p=0.083).
- 白血病患者没有较高的严重CMV事件的风险;CMV-IVIg使用与较低的峰值CMV负载相关 (p=0.040).
结论:
- 在VGCV预防期间晚期发病的白血病并没有增加CMV感染或严重疾病的风险.
- 在不影响T细胞反应的情况下,CMV-IVIg可以促进白细胞更快的恢复,并减少峰值病毒血症.
- CMV-IVIg是一种潜在的预防性替代VGCV相关的白血病.
更多相关视频
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
17.1K
11:18Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
Published on: May 7, 2012
12.7K
相关概念视频
01:22Bone Marrow Sampling and Transplants
277
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
277
01:27Disorders of Leukocytes
841
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
841